Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Goldman Sachs downgraded Regenxbio Inc RGNX, citing gene therapy’s appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offer longer-lasting effects at lower costs.Analyst Paul Choi writes that AbbVie Inc partnered ABBV-RGX-314 faces growing competition, with its invasive delivery method making it less favorable than rival treatments.Data from the ATMOSPHERE and ASCENT pivotal trials evaluating the safety and efficacy of the subretinal deliver ...